🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06066905
Recruiting Not applicable

A Study of Chidamide With AZA in MRD Positive AML After Transplant

NCT06066905 · tracked via the Priya Life Science China tracker
Sponsor
Guangdong Provincial People's Hospital
Phase
Not applicable
Started
2023-10-26
Last updated
2023-10-27

Condition(s) studied

AML, AdultMinimal Residual Disease

Investigational drug(s) / intervention(s)

chidamide and azacitidine

chidamide and azacitidine: chidamide:10mg orally,day 1 to day 6 every week, Take it for two weeks, rest for two weeks,so 28 days for a circle, 12 circles totally. azacitidine:50mg,subcutaneous injection,day 1 to day 5 every week, 28 days for a circle, 6 circles totally.

Study summary

acute myeloid leukemia (AML) is a malignant tumor of the hematopoietic system with high heterogeneity in cytogenetics and molecular biology.Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is still the primary treatment option for patients with AML and the most effective method for radical treatment of AML.Despite considerable progress in allo-HSCT over the past decade, 30%-40% of patients still relapse, and post-transplant relapse remains the leading cause of death in patients with AML.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Patients diagnosed with AML (diagnostic criteria refer to WHO2016 criteria, except M3) can detect small residual lesions (MRD) positive after allogeneic hematopoietic stem cell transplantation (allo-HSCT); 2. ≥18 years old; 3. ECOG≤3; 4. lifespan≥3 months; 5. Take contraceptive measures; 6. Sign informed consent. Exclusion Criteria: 1. Allergic to the study drug; 2. A gastrointestinal condition that prevents oral medication; 3. active infection; 4. Dysfunction of vital organs; 5. other malignancies; 6. HIV infection; 7. HBV or HCV; 8. The QT interval is prolonged; 9. Pregnant or lactating women; 10. Is participating in other clinical studies; 11. The researchers did not consider it appropriate to participate in this study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Guangdong Provincial People's Hospital Guangzhou Guangdong Recruiting

More Guangdong Provincial People's Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06066905 on ClinicalTrials.gov ↗ ← All trials in China